Zoledronic acid for prevention and treatment of osteoporosis

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 5, 2011, Pages 807-815

  Recknor, Chris ^a  

^a United Osteoporosis Centers   (United States)

Author keywords

glucocorticoid induced osteoporosis; intravenous bisphosphonate; osteopenia; osteoporosis; postmenopausal osteoporosis; zoledronic acid

Indexed keywords

ALENDRONIC ACID; ANTIBIOTIC AGENT; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; ESTROGEN; GLUCOCORTICOID; PARACETAMOL; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ARTHRALGIA; ARTICLE; BONE DENSITY; BONE MASS; BONE TURNOVER; CALCIUM BLOOD LEVEL; CHRONIC DRUG ADMINISTRATION; COMPUTER ASSISTED TOMOGRAPHY; CONJUNCTIVITIS; CONTINUOUS INFUSION; CORTICOSTEROID INDUCED OSTEOPOROSIS; CREATININE BLOOD LEVEL; DEBRIDEMENT; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG CONTROL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; EPISCLERITIS; EYE DISEASE; FEMUR FRACTURE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; FRAGILITY FRACTURE; HEADACHE; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HUMAN; HYPOCALCEMIA; IRITIS; JAW OSTEONECROSIS; KIDNEY FAILURE; LEG PAIN; MAXIMUM PLASMA CONCENTRATION; MYALGIA; OSTEOPENIA; OSTEOPOROSIS; PAGET BONE DISEASE; PATIENT COMPLIANCE; PATIENT SELECTION; POSTMENOPAUSE OSTEOPOROSIS; RECOMMENDED DRUG DOSE; RISK REDUCTION; SIDE EFFECT; UVEITIS; VERTEBRA FRACTURE;

ADULT; AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; OSTEOPOROSIS; POSTMENOPAUSE;

EID: 79952580142     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.562201     Document Type: Article

References (48)

1. Reginster JY, Burlet N. Osteoporosis: a still increasing prevalence. Bone 2006;38(2 Suppl 1):S4-9 (Pubitemid 43190767)
2. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007;22:465-75 (Pubitemid 46797130)
3. National Osteoporosis Foundation. Fast facts on osteoporosis. Washington, DC: National Osteoporosis Foundation. Available from: http://www.nof.org/ osteoporosis/diseasefacts.htm. [Accessed 24 March 2009]
4. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007;18:1023-31 (Pubitemid 47019996)
5. Cooper A, Drake J, Brankin E, PERSIST Investigators. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006;60:896-905 (Pubitemid 44082279)
6. Weiss TW, Henderson SC, McHorney CA, Cramer JA. Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Curr Med Res Opin 2007;23:2193-203 (Pubitemid 350246605)
7. Penning van-Beest FJA, Erkins JA, Olson M, Herings RMC. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 2008; 19: 511-17
8. Sambrook P. Compliance with treatment in osteoporosis patients. An ongoing problem. Aust Fam Physician 2006;35:135-8
9. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-22 (Pubitemid 44175011)
10. Siris ES, Selby PL, Saag KG, et al. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009;122:S3-13
11. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22 (Pubitemid 46698462)
12. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-809 (Pubitemid 350044800)
13. Orwoll E, Miller PD, Adachi JD, et al. Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70 mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 2010;25(10):2239-50
14. Reid DM, Devogelaer J-P, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy randomised controlled trial. Lancet 2009;373:1253-63
15. McClung M, Miller P, Recknor C, et al. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass. Obstet Gynecol 2009;114:999-1007
16. Chen T, Berenson J, Vescio R, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002;42:1228-36 (Pubitemid 35205058)
17. Novartis. Reclast package insert. East Hanover, NJ; 2009
18. Recknor C, Reid DM, Delmas P, et al. The addition of once-yearly zoledronic acid 5 mg to nonbisphosphonate treatment for osteoporosis reduced fractures in postmenopausal women: the HORIZON-Pivotal Fracture Trial [abstract]. North American Menopause Society 31st Annual Meeting; 24-27 September 2008; Orlando, FL
19. Black DM, Reid I, Cauley JA, et al. The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2010;25(Suppl 1). Available from: http://www.asb mr.org/Meetings/AnnualMeeting/AbstractDetail. aspx?aid=4781a020-dc3a-46be-b49d-f706b5509c4e. [Accessed 11 January 2011]
20. Jacobsen SJ, Goldberg J, Miles TP, et al. Hip fracture incidence among the old and very old: a population-based study of 745,435 cases. Am J Public Health 1990;80:871-3 (Pubitemid 20202209)
21. Boonen S, Autier P, Barette M, et al. Functional outcome and quality of life following hip fracture in elderly women: a one-year prospective controlled study. Osteoporos Int 2004;15:87-94 (Pubitemid 38252421)
22. American College of Rheumatology Ad Hoc Committee on Glucocorticoid- Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001;44:1496-503
23. van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 2006;79:129-37 (Pubitemid 44440440)
24. Cosman F, Eriksen E, Recknor C, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [(1-34)rhPTH] in postmenopausal osteoporosis. J Bone Miner Res 2011;26(3):503-11
25. Kurland ES, Heller SL, Diamond B, et al. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone (1-34)]. Osteoporos Int 2004;15:992-7 (Pubitemid 40064654)
26. Deal C, Tuthill K, Kriegman A. Bone loss after discontinuation of teriparatide can be prevented with a single infusion of zoledronic acid [poster]. American Society for Bone and Mineral Research 31st Annual Meeting; 11-15 September 2009; Denver, CO
27. Silverman SL, Kriegman A, Goncalves J, et al. Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid. Osteoporos Int 2010. [Epub ahead ofprint]
28. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91 (Pubitemid 351229318)
29. Grbic JT, Landesberg R, Lin SQ, et al.; Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial Research Group. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 2008;139:32-40
30. Boonen S, Sellmeyer DE, Lippuner K, et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 2008;74(5):641-8
31. Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007;89:349-53 (Pubitemid 46563912)
32. Kwek EB, Goh SK, Koh JS, et al. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 2008;39:224-31
33. Neviaser AS, Lane JM, Lenart BA, et al. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008;22:346-50 (Pubitemid 351630250)
34. Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 2008;93:2948-52
35. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008;358:1304-6 (Pubitemid 351439247)
36. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-301 (Pubitemid 40463979)
37. Armamento-Villareal R, Napoli N, Pinwar V, Novack D. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med 2006;355(19):2048-50 (Pubitemid 44708036)
38. Abrahamsen B. Adverse effects of bisphosphonates. Calcif Tissue Int 2010;86(6):421-35
39. Black DM, Kelly MP, Genant HK, et al.; Fracture Intervention Trial Steering Committee; HORIZON Pivotal Fracture Trial Steering Committee. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010;362(19):1761-71
40. McClung M, Recker R, Miller P, et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 2007;41:122-28 (Pubitemid 46901056)
41. Saag K, Lindsay R, Kriegman A, et al. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 2007;40:1238-43 (Pubitemid 46550991)
42. Lee S, Glendenning P, Inderjeeth CA. Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int 2010;22(3):741-53
43. Eriksen EF, Lyles KW, Colon-Emeric CS, et al. Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res 2009;24:1308-13
44. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTx testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65:2397-410 (Pubitemid 350100982)
45. Grbic JT, Black DM, Lyles KW, et al. Incidence of osteonecrosis of the jaw in patients receiving zoledronic acid 5 mg across the HORIZON clinical trials program. JADA 2010;141(11):1365-70
46. Lenart BA, Neviaser AS, Lyman S, et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009;20(8):1353-62
47. Rizzoli R, Akesson K, Bouxsein M, et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 2011;22(2):373-90
48. Maricic M. The role of zoledronic acid in the management of osteoporosis. Clin Rheumatol 2010;29(10):1079-84